These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20950436)

  • 1. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.
    Jochmans D; Anders M; Keuleers I; Smeulders L; Kräusslich HG; Kraus G; Müller B
    Retrovirology; 2010 Oct; 7():89. PubMed ID: 20950436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal.
    Trinité B; Zhang H; Levy DN
    Retrovirology; 2019 Jun; 16(1):17. PubMed ID: 31242909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation.
    Hsieh SH; Yu FH; Huang KJ; Wang CT
    J Virol; 2023 Sep; 97(9):e0094823. PubMed ID: 37671867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equilibrium Model of Drug-Modulated GagPol-Embedded HIV-1 Reverse Transcriptase Dimerization to Enhance Premature Protease Activation.
    Sadiq SK; Mirambeau G; Meyerhans A
    AIDS Res Hum Retroviruses; 2018 Sep; 34(9):804-807. PubMed ID: 30056738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 protease with leucine zipper fused at N-terminus exhibits enhanced linker amino acid-dependent activity.
    Yu FH; Wang CT
    Retrovirology; 2018 Apr; 15(1):32. PubMed ID: 29655366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.
    Speck RR; Flexner C; Tian CJ; Yu XF
    Antimicrob Agents Chemother; 2000 May; 44(5):1397-403. PubMed ID: 10770790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs.
    Kim JG; Shan L
    Viruses; 2022 May; 14(6):. PubMed ID: 35746649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
    Peters S; Muñoz M; Yerly S; Sanchez-Merino V; Lopez-Galindez C; Perrin L; Larder B; Cmarko D; Fakan S; Meylan P; Telenti A
    J Virol; 2001 Oct; 75(20):9644-53. PubMed ID: 11559796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
    Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
    J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.
    Davis DA; Soule EE; Davidoff KS; Daniels SI; Naiman NE; Yarchoan R
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3620-8. PubMed ID: 22508308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
    Figueiredo A; Moore KL; Mak J; Sluis-Cremer N; de Bethune MP; Tachedjian G
    PLoS Pathog; 2006 Nov; 2(11):e119. PubMed ID: 17096588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
    Lindhofer H; von der Helm K; Nitschko H
    Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.
    Reed JC; Solas D; Kitaygorodskyy A; Freeman B; Ressler DTB; Phuong DJ; Swain JV; Matlack K; Hurt CR; Lingappa VR; Lingappa JR
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33148797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of NNRTIs on HIV reverse transcriptase dimerization.
    Tachedjian G; Goff SP
    Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
    Hu K; Clément JF; Abrahamyan L; Strebel K; Bouvier M; Kleiman L; Mouland AJ
    J Virol Methods; 2005 Sep; 128(1-2):93-103. PubMed ID: 15951029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.